Your search for major depressive disorder returned 34 results

Investigators searched publication databases for randomized controlled trials evaluating cognitive training and remediation interventions among patients with MDD.

Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.

Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.

For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.

Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.

The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.

This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.

Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.

The Alpha-Stim-D trial was a noncommercial, multicenter, randomly assigned, parallel group, double-blind trial conducted at 25 primary care practices in the United Kingdom.

Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.

A cross-sectional family study sought to determine if parents’ transmission of anxiety is sex specific.

Inpatients with persistent depressive disorder were recruited at a German University Hospital for a 10-week inpatient treatment with the Cognitive Behavioral Analysis System of Psychotherapy.

For this study, patients with generalized anxiety disorder were recruited from the Nanfang Hospital in China between 2018 and 2020.

Researchers from Dalhousie University in Canada searched publication databases through September of 2020 for articles on ADHD, attention deficit disorder, bipolar disorder, and affective psychosis.

With little being known about the predictors or moderators of dTMS outcome for OCD, this study sought to examine if several theoretically relevant variables may predict and moderate treatment effects including OCD symptom severity, functional impairment, co-occurring depressive symptoms, age, gender, age of OCD onset, and family history of OCD.

While statins have both good and bad outcomes in the realm of neuropsychiatry, researchers looked at the possible associations with statins and suicidality, depression, anxiety, and seizures.

Investigators sourced data for this study from the Stockholm Major Depressive Disorder Cohort. Between 2010 and 2018, all patients in the Stockholm region who met the criteria for MDD were enrolled in the cohort.

Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.

The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.

Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.

Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.

Patients who had treatment-naïve MDD were recruited in the US between 2007 and 2013 for the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study.

Investigators looked into which treatment fared better for patients with anxiety disorders: a mindfulness-based stress reduction intervention or escitalopram.

Data for this study were sourced from 4 active treatment arms of 4 randomized, controlled trials conducted by the National Institutes of Health in the United States between 2006 and 2018.

Researchers compared the effects of 4 contemporary ablative neurosurgical procedures on treatment-resistant psychiatric symptoms.

Major depressive episodes reduce visual contrast suppression among patients with depressive disorders, a study shows.

Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.

Researchers performed a double-blind randomized study to investigate the efficacy of tDCS as an augmentation strategy to sertraline in the treatment of vascular depression.

Inpatients with schizophrenia spectrum disorders were randomly assigned to receive treatment as usual with or without a yoga-based group intervention for 4 weeks.

The REAL-ESK study was an observational, retrospective, multicenter study conducted in Italy.